Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2014

Open Access 01-12-2014 | Case report

Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports

Authors: Alexandra Carls, Julia Winter, Yeliz Enderle, Jürgen Burhenne, Matthias Gorenflo, Walter E Haefeli

Published in: Journal of Medical Case Reports | Issue 1/2014

Login to get access

Abstract

Introduction

Pulmonary hypertension is a progressive disease of diverse origin with devastating consequences in adults as well as in children. The phosphodiesterase 5 inhibitor sildenafil successfully lowers pulmonary vascular resistance. However, because of its poor enteral absorption, resulting in ineffective plasma concentrations, responses in infants and children are often erratic.

Case presentations

We report the cases of two Caucasian boys, one born at term (case 1) and one aged 2.5 years (case 2), who had structural cardiac and pulmonary defects accompanied by symptomatic pulmonary hypertension. They received sildenafil enterally and sublingually and also intravenously in one of them. Plasma samples were taken at various time points to determine the plasma concentrations of sildenafil and its partially active metabolite. Sildenafil and N-desmethyl sildenafil were quantified using a validated liquid chromatography/mass spectrometry method. Oxygen partial pressure was determined from routine arterial blood gas samples.

Conclusion

In agreement with previous observations in adults, we found that sublingual sildenafil was more extensively absorbed in our two pediatric patients. After sublingual administration, sildenafil plasma concentrations increased by 314% to 361% compared to enteral dosing. Concurrently, the metabolic ratio increased, suggesting not only that the overall absorption was enhanced but also that first-pass metabolism was partially bypassed. In case 2, the free fraction of sildenafil was 0.9%, which is considerably less than in adults (4%), suggesting that, in case 2, higher plasma concentration would have been needed to achieve effects similar to those in adults. Sublingual sildenafil appears to be a promising alternative route of administration in children with poor enteral absorption.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wardle AJ, Tulloh RM: Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Arch Dis Child Educ Pract Ed. 2013, 98: 141-147. 10.1136/archdischild-2013-303981.CrossRefPubMed Wardle AJ, Tulloh RM: Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Arch Dis Child Educ Pract Ed. 2013, 98: 141-147. 10.1136/archdischild-2013-303981.CrossRefPubMed
2.
go back to reference Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002, 53 (Suppl 1): 5S-12S.CrossRefPubMedPubMedCentral Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002, 53 (Suppl 1): 5S-12S.CrossRefPubMedPubMedCentral
3.
go back to reference Ahsman MJ, Witjes BC, Wildschut ED, Sluiter I, Vulto AG, Tibboel D, Mathot RA: Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed. 2010, 95: F109-F114. 10.1136/adc.2009.168336.CrossRefPubMed Ahsman MJ, Witjes BC, Wildschut ED, Sluiter I, Vulto AG, Tibboel D, Mathot RA: Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed. 2010, 95: F109-F114. 10.1136/adc.2009.168336.CrossRefPubMed
4.
go back to reference Apitz C, Reyes JT, Holtby H, Humpl T, Redington AN: Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. J Am Coll Cardiol. 2010, 55: 1456-1462. 10.1016/j.jacc.2009.11.065.CrossRefPubMed Apitz C, Reyes JT, Holtby H, Humpl T, Redington AN: Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. J Am Coll Cardiol. 2010, 55: 1456-1462. 10.1016/j.jacc.2009.11.065.CrossRefPubMed
5.
go back to reference Lammers AE, Haworth SG, Pierce CM: Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. Cardiol Young. 2006, 16: 84-86. 10.1017/S1047951105002155.CrossRefPubMed Lammers AE, Haworth SG, Pierce CM: Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. Cardiol Young. 2006, 16: 84-86. 10.1017/S1047951105002155.CrossRefPubMed
6.
go back to reference Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL: Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011, 37: 502-509. 10.1007/s00134-010-2065-4.CrossRefPubMed Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL: Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011, 37: 502-509. 10.1007/s00134-010-2065-4.CrossRefPubMed
7.
go back to reference Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM: Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail. 2011, 4: 198-206. 10.1161/CIRCHEARTFAILURE.110.957050.CrossRefPubMed Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM: Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail. 2011, 4: 198-206. 10.1161/CIRCHEARTFAILURE.110.957050.CrossRefPubMed
8.
go back to reference Nahata MC, Morosco RS, Brady MT: Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm. 2006, 63: 254-257. 10.2146/ajhp050208.CrossRefPubMed Nahata MC, Morosco RS, Brady MT: Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm. 2006, 63: 254-257. 10.2146/ajhp050208.CrossRefPubMed
9.
go back to reference Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL: A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012, 125: 324-334. 10.1161/CIRCULATIONAHA.110.016667.CrossRefPubMed Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL: A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012, 125: 324-334. 10.1161/CIRCULATIONAHA.110.016667.CrossRefPubMed
11.
go back to reference Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adatia I, Hanna B, Feinstein J, Fineman J, Raj U, Humpl T, Pediatric Pulmonary Hypertension Network (PPHNet): Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med. 2013, 187: 572-575. 10.1164/rccm.201210-1928PP.CrossRefPubMed Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adatia I, Hanna B, Feinstein J, Fineman J, Raj U, Humpl T, Pediatric Pulmonary Hypertension Network (PPHNet): Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med. 2013, 187: 572-575. 10.1164/rccm.201210-1928PP.CrossRefPubMed
12.
go back to reference De Siati M, Saugo M, Franzolin N: The start of pharmacological activity after sublingual administration of sildenafil citrate in 30 patients affected by erectile dysfunction. Arch Ital Urol Androl. 2003, 75: 18-20.PubMed De Siati M, Saugo M, Franzolin N: The start of pharmacological activity after sublingual administration of sildenafil citrate in 30 patients affected by erectile dysfunction. Arch Ital Urol Androl. 2003, 75: 18-20.PubMed
13.
go back to reference Freitas AF, Bacal F, Oliveira JL, Santos RHB, Moreira LFP, Silva CR, Mangini S, Carneiro RMD, Fiorelli AI, Bocchi EA: [Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure] [in English Portuguese and Spanish]. Arq Bras Cardiol. 2009, 92: 116-126.CrossRef Freitas AF, Bacal F, Oliveira JL, Santos RHB, Moreira LFP, Silva CR, Mangini S, Carneiro RMD, Fiorelli AI, Bocchi EA: [Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure] [in English Portuguese and Spanish]. Arq Bras Cardiol. 2009, 92: 116-126.CrossRef
14.
go back to reference Zayed R, Kamel AO, Shukr M, El-Shamy A: An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. Acta Pharm. 2012, 62: 411-432.CrossRefPubMed Zayed R, Kamel AO, Shukr M, El-Shamy A: An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. Acta Pharm. 2012, 62: 411-432.CrossRefPubMed
15.
go back to reference Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N: Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000, 50: 99-107. 10.1046/j.1365-2125.2000.00245.x.CrossRefPubMedPubMedCentral Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N: Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000, 50: 99-107. 10.1046/j.1365-2125.2000.00245.x.CrossRefPubMedPubMedCentral
16.
go back to reference Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002, 53 (Suppl 1): 21S-30S.CrossRefPubMedPubMedCentral Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002, 53 (Suppl 1): 21S-30S.CrossRefPubMedPubMedCentral
17.
go back to reference de Wildt SN: Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol. 2011, 7: 935-948. 10.1517/17425255.2011.577739.CrossRefPubMed de Wildt SN: Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol. 2011, 7: 935-948. 10.1517/17425255.2011.577739.CrossRefPubMed
18.
go back to reference Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM: Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther. 2007, 82: 265-274. 10.1038/sj.clpt.6100138.CrossRefPubMed Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM: Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther. 2007, 82: 265-274. 10.1038/sj.clpt.6100138.CrossRefPubMed
19.
go back to reference Hyland R, Roe EG, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001, 51: 239-248.CrossRefPubMedPubMedCentral Hyland R, Roe EG, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001, 51: 239-248.CrossRefPubMedPubMedCentral
20.
go back to reference Karatza AA, Bush A, Magee AG: Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005, 100: 267-273. 10.1016/j.ijcard.2004.09.002.CrossRefPubMed Karatza AA, Bush A, Magee AG: Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005, 100: 267-273. 10.1016/j.ijcard.2004.09.002.CrossRefPubMed
Metadata
Title
Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports
Authors
Alexandra Carls
Julia Winter
Yeliz Enderle
Jürgen Burhenne
Matthias Gorenflo
Walter E Haefeli
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-8-171

Other articles of this Issue 1/2014

Journal of Medical Case Reports 1/2014 Go to the issue